Compare BioNTech SE - ADR (BNTX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs The Coca-Cola Co K — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while The Coca-Cola Co K trades at $83.2 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 15.6× BioNTech SE - ADR's market cap, and The Coca-Cola Co K pays a 2.55% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KO | |
|---|---|---|
Market Cap | $22.86B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $84.25 |
52-Week Low | $83.89 | $65.67 |
Enterprise Value | $6.53B | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 27.8% net margin and 45.8% ROE, though valuation multiples like P/E of 26.5 appear elevated. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
The outlook remains positive with a $89.75 analyst target suggesting 6.5% upside, supported by dividend reliability. Key risks include high debt levels and regional demand volatility. The stock presents a steady growth opportunity with moderate upside potential balanced by valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
